Board of Directors
Dr. Anand Kumaresh Tharmaratnam
Dr. Tharmaratnam is Novotech’s Chief Executive Officer and Chairman, bringing more than 30 years of experience across the global CRO and life sciences industry. He has served on the Novotech Board since 2021 and has been closely involved in guiding the company’s strategic direction and growth. A UK-trained physician specializing in anesthesia and critical care, Anand previously spent 23 years at Quintiles and its successor organization, IQVIA, including 10 years on their global executive committees as Head of Asia and Japan. As CEO and Chairman, he is leading Novotech into its next phase of global expansion, strengthening scientific capabilities, and delivering high-quality outcomes for biotech clients worldwide.
Joel Thickins
Joel Thickins is a Partner and the Co-Head of Asia at TPG, co-Managing Partner for TPG Capital Asia, and the Managing Partner of TPG Emerging Companies Asia (TĒCA). He is the current Chairman of Greencross Limited, Australia and New Zealand’s largest pet wellness and vets platform, and InvoCare, a leading provider of funeral, cemetery, and crematoria services in Australia, New Zealand, and Singapore, and the Deputy Chairman of Novotech, a globally recognized full-service biotech specialist clinical research organization. Previously, Mr. Thickins served as Chairman at iNova Pharmaceuticals, a leading independent consumer healthcare and medicine products company, Made Group, one of Australia’s largest healthy food and beverage businesses, and Funlab, Australia’s premier creator of competitive socialising experiences. He is also a former Director of Ingham’s and Accolade Wines.
TAN Hwee Loo
TAN is a Non-Executive Director of Novotech and Head of Asia within the Private Equity department at GIC, where she oversees investments across China, India, Southeast Asia, Japan, Korea, and Australia/New Zealand. She joined GIC in 2001 and has held a range of senior leadership roles across global investment strategy and private equity investing, including appointments in London and Singapore. Her experience spans economic research, private equity fund investment, secondaries, co-investments, direct investments and global strategy and risk. Within GIC, she serves on the Human Resource Committee and the Resilience Fund panel, and externally she is a member of the Investment Committee of the Singapore University of Social Sciences.
Vincent Wong
Vincent Wong is a Firm Partner with TPG Capital and Co-Head of Healthcare for TPG Asia and is based in Melbourne, where he works in TPG’s Australian team. Prior to joining TPG in 2011, Vincent served in the corporate advisory division at Goldman Sachs Australia. Vincent graduated from the University of Melbourne with BCommerce and BLaws (Honors).
Korwin Chiu
Korwin is a Senior Vice President at GIC, where he oversees healthcare private equity investments across the Asia-Pacific region. He brings more than 15 years of experience investing in the healthcare sector. Prior to joining GIC in 2012, he held roles at Court Square Capital in New York and Bank of America.
Ethan Park Jung Ryun
Ethan is a Managing Director at Temasek, where he leads healthcare and life sciences investment activities across Europe, the Middle East and Africa (EMEA), and Southeast Asia (SEA). Prior to Temasek, he held roles at SK Corporation in Seoul, Korea. He serves on the boards of several healthcare and life sciences companies.
Zubin Jamshed Irani
Zubin is Partner and Head of Operations for TPG in Asia, where he is responsible for the performance of TPG’s portfolio across Asia Pacific. He brings over 27 years' experience in building strong teams, driving performance, and managing change within businesses. For the last 10 years, Zubin has built TPG’s value creation capability and operations team in Asia. He has worked across the consumer, healthcare, financial services, technology and industrial sectors. Zubin works closely with the management teams in TPG’s portfolio companies, guiding the execution of the value creation plan and driving performance improvement. He has also been an Exco/Board member for several TPG portfolio companies in Asia over the past few years.
Elaine June Cheung
Elaine has over 30 years of experience as a global CFO and Board Director across healthcare, consumer goods, and education. Her leadership roles include Dole, Temasek, VF Corporation, and Zuellig Pharma. She serves on multiple global boards and is a respected Audit Committee Chair, providing strong governance and financial oversight.
Dr. Fred Ehrenkranz Cohen
Dr. Cohen is a Senior Advisor to TPG where he was a Partner and co-founder of TPG Biotech. He currently serves as the Chairman of Monograph Capital Partners, a life sciences venture capital group. Prior to TPG, Dr. Cohen was a Professor of Medicine and Pharmacology at UCSF. He has extensive experience in biotechnology investing and governance, and has served on the boards of multiple biotechnology and pharmaceutical companies, including Quintiles Transnational (NYSE: Q), Progyny (NASDAQ: PGNY), Aptalis and BioCryst Pharmaceuticals (NASDAQ: BCRX). He currently serves on the boards of CareDx (NASDAQ: CDNA), Intellia (NASDAQ: NTLA) and Kyverna Therapeutics (NASDAQ: KVTX)
Senior Management
Dr. Anand Kumaresh Tharmaratnam
Dr. Tharmaratnam is Novotech’s Chief Executive Officer and Chairman, bringing more than 30 years of experience across the global CRO and life sciences industry. He has served on the Novotech Board since 2021 and has been closely involved in guiding the company’s strategic direction and growth. A UK-trained physician specializing in anesthesia and critical care, Anand previously spent 23 years at Quintiles and its successor organization, IQVIA, including 10 years on their global executive committees as Head of Asia and Japan. As CEO and Chairman, he is leading Novotech into its next phase of global expansion, strengthening scientific capabilities, and delivering high-quality outcomes for biotech clients worldwide.
Vivek Kapoor
Vivek is Novotech’s Chief Financial Officer, responsible for financial planning and controls, and overseeing Corporate Finance, Accounting, Procurement, Real Estate, Shared Services, Investor Relations, and IT Infrastructure. He is a senior finance leader with more than 30 years of experience across life sciences, healthcare, and technology in Asia Pacific, Japan, the Middle East, and Africa. Prior to Novotech, Vivek served as CFO AMEA at Guardant Health and CFO for Asia Pacific at IQVIA, where he supported significant growth, acquisitions, and digital transformation.
Michael Stibilj
Michael is Novotech’s Chief Operations Officer, overseeing Global Clinical Services across Asia Pacific, Europe, the US, and Japan, as well as Global Project Management, Global Biometrics, Operational Strategy Leads, and Operational Medical Services. Michael has more than 25 years of experience in the CRO industry. Prior to joining Novotech in 2017, he spent 15 years building and leading operations across Asia for Quintiles/IQVIA and served as a Senior Advisor to TPG Capital, driving transformational growth and scalable global delivery.
Tim Bray
Tim is Novotech’s Chief Human Resources Officer, leading the company’s people and culture strategy and shaping how Novotech attracts, engages, and retains talent globally. He oversees Human Resource Management and is strengthening Talent Acquisition, Organizational Development, and Learning & Development. Tim brings deep global HR leadership experience across the life sciences and CRO sectors, having held senior roles at Quintiles/IQVIA, Bayer, and Novartis. He has led large-scale workforce growth, talent transformation, and leadership development across the Americas, EMEA, and Asia-Pacific markets.
Dr. Judith Ng-Cashin
Dr. Ng-Cashin is Novotech’s Chief Medical Officer (CMO), leading the company’s Therapeutic & Scientific Strategy, Quality Assurance, and Drug Development Consulting functions. She joined Novotech in 2023, bringing more than 20 years of international experience across pharmaceutical, biotech, and CRO environments. Based in the United States, Judith provides strategic medical leadership across global programs and multi-regional trials, ensuring scientific integrity and high-quality delivery for clients and patients. She has held senior executive roles at Syneos Health, INC Research, Quintiles, Eagle Pharmaceuticals, AoBiome, and GlaxoSmithKline.
Prashant Dhami
Prashant is Novotech’s Chief Strategy Officer, responsible for Corporate Strategy and Development, Mergers & Acquisitions, and value creation initiatives. He also oversees Marketing and Communications and supports the launch of new offerings and customer segments. Prashant brings extensive experience in strategy, commercial leadership, and healthcare advisory, having held senior roles at IQVIA across Asia Pacific, including P&L leadership of consulting, real-world evidence, and commercial services businesses. He is also a Senior Advisor to TPG, providing strategy and value creation support across its healthcare portfolio.
Barry Murphy
Barry is Novotech’s Chief Commercial Officer (CCO), leading Business Development and Sales Operations across all markets, including Global Sales Operations and Key Account Management. He joined Novotech in 2014 and has played a key role in scaling the company’s commercial capabilities, expanding its sales focus from emerging biotech to established biotech and mid-sized pharmaceutical companies. Barry began his career as a pharmacist and brings deep CRO industry experience, having previously held multiple contract management roles at ICON plc.
Andy Liu
Andy is Novotech’s Managing Director, Greater China and Global Labs, responsible for managing and growing the company’s regional business across Mainland China, Taiwan, and Hong Kong, as well as leading global laboratory services. Based in Shanghai, Andy brings more than a decade of CRO industry experience, having held multiple senior leadership roles at Covance, including General Manager of Central Laboratory Services for Asia Pacific, where he led large, multi-functional teams across multiple sites and drove regional operational growth.
Dr. Yooni Kim
Dr. Kim is Novotech’s Chief Product Officer (CPO), dedicated to enhancing the global customer experience and strategically transforming service offerings into core products with a focus on inbound growth in the JAPAC region and large strategic opportunities. She ensures customer-centricity is embedded across Novotech’s service delivery and solutions. She brings more than 25 years of clinical research experience across CRO, pharmaceutical, and academic settings – including operational leadership roles in GSK and ICON - she joined Novotech in 2016. Having previously served as Managing Director of Asia Pacific and Vice President of Clinical Services, she now leads Novotech’s global service productization and customer experience management.